Dari milis lain, dari Ameika, dari grup medisch : There are many other companies working on vaccines for the Wuham coronavirus. Including China themselves. Vaccinnnya Gilead terbukti effektif terhadarp Sars dan Ebola. Tiongkok mencoba vaccin ini dengan penambahan Chloroquin?
https://cen.acs.org/business/Biotech-firms-tackle-Wuhan-virus/98/i4 The US Centers for Disease Control and Prevention (CDC) announced the first case of the virus in the US on Jan. 21. In the following days, several biotech companies, quick to see opportunity for both business and attention, announced plans to tackle the virus. Gaithersburg, Maryland–based Novavax said it would attempt to make a vaccine for the virus, which is being called 2019-nCoV. Novavax’s stock rose 70% within a day of the news. The company followed up by announcing plans to raise $100 million in a public sale of its stock. Inovio Pharmaceuticals, which develops DNA-based vaccines, announced a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to design and test a vaccine for 2019-nCoV. The company has experience designing experimental vaccines for Ebola virus, Zika virus, and a deadly coronavirus that causes Middle East respiratory syndrome (MERS). The San Francisco infectious-disease company Vir Biotechnology announced that it would investigate whether any monoclonal antibodies that it has on hand for other coronaviruses—such MERS and severe acute respiratory syndrome (SARS)—could also defuse 2019-nCoV. And Moderna Therapeutics announced that it is working with the National Institutes of Health “on a potential vaccine response” to the virus. Moderna already has multiple messenger RNA-based vaccines undergoing clinical testing. The company also announced funding from CEPI. Academic scientists have also gone into action. Purdue University scientists Andrew Mesecar and Arun Ghosh announced that they will test existing small molecules— originally designed to target a SARS virus protein called the 3CL protease—against the new virus. Mesecar says Purdue has a biosafety level 3 facility to conduct the work in. On the diagnostics front, the CDC has developed a real-time reverse transcription-polymerase chain reaction (rRT-PCR) test to confirm the presence of the new virus in clinical samples. It plans to share the test with health officials in the US and abroad in “the coming days and weeks.” At least one company, Salt Lake City–based Co-Diagnostics, is advertising plans to develop its own PCR diagnostics for the virus. On Wed, Feb 5, 2020 at 4:51 wrote: > The antiviral drug made by Gilead pharmaceutical company , Remdesivir, > will be tested in Beijing and Wuhan to treat the novel coronavirus > infection. This drug was used for SARS and Ebola in the past. > The shares of Gilead jumps up in the stock market. > HG >
